EyePoint Pharmaceuticals, Inc.
EYPT
$4.13
-$0.49-10.61%
| Weiss Ratings | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.29 | |||
| Price History | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -29.16% | |||
| 30-Day Total Return | -30.70% | |||
| 60-Day Total Return | -50.48% | |||
| 90-Day Total Return | -55.25% | |||
| Year to Date Total Return | -48.57% | |||
| 1-Year Total Return | -80.08% | |||
| 2-Year Total Return | 24.40% | |||
| 3-Year Total Return | -65.44% | |||
| 5-Year Total Return | -50.83% | |||
| 52-Week High % Change | -80.46% | |||
| 52-Week Low % Change | 10.26% | |||
| Price | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $23.65 | |||
| 52-Week Low Price | $4.19 | |||
| 52-Week Low Price (Date) | Apr 07, 2025 | |||
| 52-Week High Price (Date) | Apr 12, 2024 | |||
| Valuation | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 317.53M | |||
| Enterprise Value | -30.28M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.31 | |||
| Earnings Per Share Growth | 25.87% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 6.89 | |||
| Price/Book (Q) | 0.94 | |||
| Enterprise Value/Revenue (TTM) | -0.70 | |||
| Price | $4.13 | |||
| Enterprise Value/EBITDA (TTM) | 0.21 | |||
| Enterprise Value/EBIT | 0.21 | |||
| Market Cap Category | Small Cap | |||
| Dividends and Shares | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 64.56M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 617 926 5000 | |||
| Address | 480 Pleasant Street Watertown, MA 02472 | |||
| Website | eyepointpharma.com | |||
| Country | United States | |||
| Year Founded | 1987 | |||
| Profitability | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -337.05% | |||
| Profit Margin | -302.42% | |||
| Management Effectiveness | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -23.57% | |||
| Return on Equity | -- | |||
| Income Statement | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 43.27M | |||
| Total Revenue (TTM) | 43.27M | |||
| Revenue Per Share | $0.67 | |||
| Gross Profit (TTM) | 46.54M | |||
| EBITDA (TTM) | -144.31M | |||
| EBIT (TTM) | -145.85M | |||
| Net Income (TTM) | -130.87M | |||
| Net Income Avl. to Common (TTM) | -130.87M | |||
| Total Revenue Growth (Q YOY) | -17.39% | |||
| Earnings Growth (Q YOY) | -193.63% | |||
| EPS Diluted (TTM) | -2.31 | |||
| EPS Diluted Growth (Q YOY) | -91.78% | |||
| Balance Sheet | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 370.91M | |||
| Cash Per Share (Q) | $5.75 | |||
| Total Current Assets (Q) | 383.31M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 336.50M | |||
| Current Ratio (Q) | 7.815 | |||
| Book Value Per Share (Q) | $4.93 | |||
| Total Assets (Q) | 418.47M | |||
| Total Current Liabilities (Q) | 49.05M | |||
| Total Debt (Q) | 23.11M | |||
| Total Liabilities (Q) | 81.96M | |||
| Total Common Equity (Q) | 336.50M | |||
| Cash Flow | EYPT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -219.36M | |||
| Cash from Financing (TTM) | 164.02M | |||
| Net Change in Cash (TTM) | -181.56M | |||
| Levered Free Cash Flow (TTM) | -70.48M | |||
| Cash from Operations (TTM) | -126.23M | |||
